Alpha-Beta regulatory update

ABTI received notice of allowance for a U.S. patent covering the use of Betafectin in pharmaceutical preparations that stimulate platelet production. In preclinical trials, Betafectin alone or in combination with certain growth factors can stimulate platelet precursor and white blood cell production, without the side effects associated with pro-inflammatory cytokines, ABTI said.

The Worcester, Mass., company said Betakine may be a useful therapy to accelerate the recovery of white blood cells and platelets following chemotherapy. ABTI is completing the development of a clinical strategy to test Betafectin in various chemotherapy-related indications. ...